A two-part, Phase 1 study of Rhenium-186 NanoLiposome (186RNL) delivered by convection enhanced delivery (CED) for recurrent or progressive childhood ependymoma and high-grade glioma (HGG) (SNO 2022) - Sep 28, 2022 - Abstract #CTNI-19; Pres time: Nov 18, 2022; 07:30 PM - 09:30 PM; Location: West/Central Hall; P1/2 | "The primary endpoint for Cohort 2A is overall response rate (ORR) by Radiographic Assessment in Pediatric Neuro-Oncology (RAPNO) criteria and the primary endpoint for Cohort 2B is progression free survival. Planned enrollment will begin in early 2023."
Clinical • P1 data • Brain Cancer • Ependymoma • Glioblastoma • Glioma • Oncology • Pediatrics • Solid Tumor
|
|
Ashley Plant-Fox, M.D; Michael DeCuypere; Sandi Lam; Carla Quijano; Lisa Sereno; Ande Bao, Ph.D.; Norman LaFrance; Marc Hedrick; Andrew J. Brenner, MD.,Ph.D
|